Fenflurmaine in CKDL5 Deficiency Disorder (CDD)

Brief description of study

The purpose of this study is to study the effectivenss of treating CDKL5 Deficiency Disorder with Fenfluramine. This treatment uses an investigational drug named fenfluramine. Investigational means that the Food and Drug Administration (FDA) has not yet approved the drug for this use. How well this investigational drug works or even if it is safe has not yet been proven through clinical trials. The study will enroll 10 patients, ages 2-35 years old, with a confirmed genetic/clinical diagnosis of CDKL5 Deficiency Disorder (CDD) in an open label trial of fenfluramine for seizure control.

Clinical Study Identifier: s18-01530
ClinicalTrials.gov Identifier: NCT03861871
Principal Investigator: Orrin Devinsky.

If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.